As per MRFR analysis, the US Liquid Biopsy Market Size was estimated at 2.31 (USD Billion) in 2023. The US Liquid Biopsy Market Industry is expected to grow from 2.55(USD Billion) in 2024 to 8.03 (USD Billion) by 2035. The US Liquid Biopsy Market CAGR (growth rate) is expected to be around 10.999% during the forecast period (2025 - 2035).
The US Liquid Biopsy Market is witnessing significant growth, driven by a rising demand for non-invasive diagnostic solutions. As more healthcare professionals and patients seek early detection and monitoring of cancer, the ability of liquid biopsies to detect circulating tumor DNA and other biomarkers provides a compelling alternative to traditional tissue biopsies. Moreover, advancements in genomic technologies and an increase in research funding from government agencies are contributing to the development and validation of innovative liquid biopsy tests.
Opportunities in the US market are expanding as regulatory bodies, such as the FDA, provide clearer guidelines for the approval of liquid biopsy tests, paving the way for new products to enter the market. The growing prevalence of cancer and the necessity for personalized medicine further enhance the potential for liquid biopsy adoption in clinical practice. Additionally, the integration of liquid biopsy tests into routine healthcare workflows presents a chance for healthcare providers to improve patient outcomes and streamline diagnostic processes.
In recent times, collaborations and partnerships between biotech firms and academic institutions are on the rise, facilitating the sharing of knowledge and technology in the development of liquid biopsy solutions. The increasing interest in precision medicine has also led to an uptick in clinical trials focusing on liquid biopsies, promoting innovation and efficacy. As patients become more aware of liquid biopsy options, the market is likely to experience increased acceptance, aligning with the broader trend of patient-centric healthcare in the US. Overall, these trends indicate a dynamic and rapidly evolving landscape for liquid biopsies in the United States, underscoring their potential impact on cancer diagnostics and management.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The US has seen a notable rise in cancer cases, with the American Cancer Society reporting approximately 1.9 million new cancer cases diagnosed in 2021 alone. This rising prevalence of cancer drives the demand for innovative diagnostic methods like liquid biopsies. As the US Liquid Biopsy Market Industry evolves, major institutions such as the National Cancer Institute and the American Society of Clinical Oncology are recognizing the importance of liquid biopsies for early detection and monitoring of cancer.
Moreover, the United States government is increasing funding for research and development related to cancer diagnostics, which enhances the scope for liquid biopsy technologies across the nation. This upward trend in cancer cases and government backing provides a strong impetus for the growth of the US Liquid Biopsy Market Industry.
Technological advancements have significantly improved the efficiency and accuracy of liquid biopsy techniques, such as circulating tumor DNA (ctDNA) analysis. Organizations like Guardant Health and Foundation Medicine are at the forefront, developing cutting-edge liquid biopsy solutions that allow for non-invasive cancer diagnostics. These advancements are influenced by increased funding for Research and Development from both private and public sectors.
A report by the National Institutes of Health indicates that federal funding for genomic and personalized medicine initiatives has grown substantially, enhancing the capabilities of liquid biopsies. This focus on innovation bolsters the US Liquid Biopsy Market Industry, encouraging more healthcare providers to adopt these state-of-the-art diagnostic methods.
There is a growing awareness and preference for minimally invasive diagnostic methods amongst patients and healthcare providers. Liquid biopsies offer a less painful alternative to traditional biopsies, thus appealing to patients who prioritize patient comfort. Healthcare providers in the US are increasingly promoting liquid biopsies as a viable option for cancer monitoring and detection, with organizations like the American Society of Clinical Oncology endorsing their use.
The National Cancer Institute states that patient preference for non-invasive procedures has increased by over 25% in recent years, reflecting a wider trend towards non-invasive techniques in the healthcare industry. This shift in patient preferences supports the future growth of the US Liquid Biopsy Market Industry.
The regulatory landscape in the US has become increasingly supportive towards the development and commercialization of liquid biopsies. The Food and Drug Administration has introduced frameworks that expedite the approval process for innovative diagnostic tests. This is evident from the FDA’s Breakthrough Devices Program, which aids in accelerating the development of technologies that may provide more effective treatment or diagnosis. As per FDA announcements, the approval of liquid biopsy products has more than doubled over the last five years.
This supportive framework is crucial for companies looking to enter the US Liquid Biopsy Market Industry, allowing them to bring their solutions to the market faster and more efficiently.
The US Liquid Biopsy Market is witnessing significant growth due to its non-invasive approach to cancer diagnostics, as it allows for early detection and monitoring of cancer through the analysis of biological fluids. The market can be categorized based on Types, which include Circulating Tumor Cells, Circulating Tumor DNA, Extracellular Vesicles, and Others. Circulating Tumor Cells have emerged as a pivotal tool for understanding cancer metastasis and treatment responses, enabling oncologists to tailor therapies based on real-time information.
Circulating Tumor DNA holds substantial relevance as it provides insights into tumor genetics from a simple blood draw, facilitating personalized medicine strategies by tracking mutations and therapeutic resistance without the need for invasive biopsies. Extracellular Vesicles, which carry proteins and nucleic acids, play an essential role as biomarkers for various cancers and are increasingly recognized for their ability to provide information about a tumor's microenvironment, aiding in the identification of aggressive cancers. Furthermore, the "Others" category encompasses a variety of additional biomarkers and methodologies made possible by advancements in molecular biology and technology, which are contributing to the diversification of liquid biopsy applications.
Factors driving growth in the US Liquid Biopsy Market include a rising prevalence of cancer, continual advancements in technology that enhance sensitivity and specificity, and a shift towards precision medicine. However, challenges such as regulatory hurdles and reimbursement issues remain prevalent, while opportunities lie in expanding research collaborations and increasing awareness among healthcare providers. Overall, the diversification within the Types segment reflects the potential for innovation that can significantly impact cancer diagnostics and patient management in the US healthcare landscape.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Application segment of the US Liquid Biopsy Market plays a critical role in the healthcare landscape, driven by increasing adoption in Cancer Therapeutic Application and Reproductive Health. The Cancer Therapeutic Application dominates this market due to the rising prevalence of various cancers among the population, leading to a growing demand for innovative and non-invasive diagnostic tools that enhance personalized treatment options. Reproductive Health also holds significant importance, offering valuable insights into genetic disorders and pregnancy-related conditions, thereby facilitating early intervention strategies.
Other applications within this segment further broaden the utility of liquid biopsies, addressing a variety of health concerns. As the US government prioritizes precision medicine, advancements in liquid biopsy technology are expected to lead to greater patient outcomes, fueling market growth. The increasing focus on minimally invasive procedures aligns with patient preferences, creating opportunities for expansion across different healthcare settings. Overall, the rich landscape of applications in the liquid biopsy sector presents valuable opportunities for healthcare providers aiming to improve diagnostic accuracy and patient management.
The US Liquid Biopsy Market is experiencing significant growth, particularly within the Sample segment which includes Blood Samples, Urine Samples, and Other biological fluids. Blood Samples are crucial as they offer a non-invasive method for detecting cancer biomarkers, making them the most widely utilized option among clinicians and researchers. Urine Samples are also gaining traction due to their ease of collection and the potential to detect a range of conditions, providing a viable alternative for patients who may prefer less invasive procedures.
The Other segment encompasses various bodily fluids that can be analyzed, such as saliva, which is emerging as a promising avenue for liquid biopsy applications. The rising prevalence of cancer and increasing demand for early detection methods are pivotal drivers influencing this market segment. Moreover, advancements in technology and regulatory support further enhance accessibility and adoption of these liquid biopsy approaches. Therefore, the diverse applications and benefits of these different sample types make them integral to the overall landscape of the US Liquid Biopsy Market, fostering continuous innovation and growth in the industry.
The US Liquid Biopsy Market has experienced significant growth over the past few years, driven by advancements in technology and increasing demand for non-invasive diagnostics in oncology. This competitive landscape is characterized by numerous players offering innovative solutions that allow for the detection of cancer-related biomarkers through blood samples. The focus on personalized medicine and targeted therapies has further propelled interest and investment in liquid biopsies, making it a vital segment within the diagnostic industry. Companies are increasingly enhancing their product offerings and forming strategic collaborations to foster innovation and improve testing accuracy, thereby intensifying the competition. As players strive to capture greater market share, the emphasis on regulatory approvals and clinical validations becomes crucial in establishing trust and credibility in the market.
Foundation Medicine, operating within the US Liquid Biopsy Market, has established a strong foothold thanks to its innovative genomic profiling solutions that aid in precision medicine. The company leverages its proprietary technology to analyze tumor DNA from blood samples, enabling oncologists to make informed treatment decisions tailored to individual patients. Foundation Medicine’s strengths lie in its comprehensive test offerings and collaborations with both pharmaceutical companies and diagnostic laboratories, which enhance its market presence. Furthermore, their focus on expanding access to their tests through partnerships and reimbursement strategies has solidified their position in the industry. The company is well-regarded for its dedication to advancing cancer care through its precision diagnostics, fostering an ecosystem that promotes heightened awareness and utilization of liquid biopsy technologies.
Sysmex Inostics, a significant player in the US Liquid Biopsy Market, delivers crucial products and services that focus on cancer diagnostics through liquid biopsy technologies. Their key offerings include specialized genetic testing that provides insights into tumor mutations and their potential response to therapies. Sysmex Inostics’ strengths lie in its advanced testing technologies and meaningful collaborations with healthcare providers that enable efficient integration of their solutions in clinical practice. The company actively engages in research and development efforts, ensuring that its products are at the forefront of innovation in the liquid biopsy space. They have made strategic moves including mergers and acquisitions to enhance their capabilities, expand their product portfolio, and strengthen their competitive position in the market. Their commitment to providing high-quality diagnostic services tailored to the US market enhances their presence and operational efficiency in this rapidly evolving landscape.
Recent developments in the US Liquid Biopsy Market have been marked by significant advancements and strategic movements among key players. Foundation Medicine launched its new liquid biopsy test, enhancing genomic profiling capabilities. Sysmex Inostics, focused on cancer diagnostics, continues to innovate through cutting-edge technologies. In August 2023, Guardant Health announced a collaboration with another prominent firm to enhance its precision oncology offerings. A notable merger occurred in September 2023, when Freenome acquired a subsidiary of Biocept to expand its testing capabilities and operational footprint. The market is currently valued at several billion USD, with projections indicating substantial growth driven by increasing adoption of non-invasive diagnostics.
Regulatory approvals by the FDA for innovative liquid biopsy tests have also spurred confidence in this market, with a focus on improving patient outcomes through early cancer detection. Other companies such as GRAIL and Natera are actively developing new assays, contributing to the dynamic landscape of the US Liquid Biopsy Market, which has seen rapid evolution and increasing investments over the past few years.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 2.31(USD Billion) |
| MARKET SIZE 2024 | 2.55(USD Billion) |
| MARKET SIZE 2035 | 8.03(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 10.999% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Billion |
| KEY COMPANIES PROFILED | Foundation Medicine, Sysmex Inostics, Strata Oncology, Freenome, Biocept, Exact Sciences, Personal Genome Diagnostics, Caris Life Sciences, Natera, Qiagen, Cynvenio, Trovagene, Epic Sciences, Guardant Health, GRAIL |
| SEGMENTS COVERED | Types, Application, Sample |
| KEY MARKET OPPORTUNITIES | Increasing cancer prevalence, Advancements in sequencing technology, Growing demand for non-invasive tests, Integration with precision medicine, Expansion of biomarker research |
| KEY MARKET DYNAMICS | Rising cancer prevalence, Increased demand for non-invasive testing, Technological advancements in diagnostics, Growing research funding, Favorable regulatory environment |
| COUNTRIES COVERED | US |
Frequently Asked Questions (FAQ) :
The US Liquid Biopsy Market is anticipated to reach a value of 2.55 billion USD in 2024.
By 2035, the US Liquid Biopsy Market is expected to grow significantly to a value of 8.03 billion USD.
The US Liquid Biopsy Market is projected to have a CAGR of 10.999 percent during the forecast period from 2025 to 2035.
Circulating Tumor DNA is projected to hold the largest market share in 2035, valued at 3.53 billion USD.
Major players in the market include Foundation Medicine, Sysmex Inostics, Strata Oncology, and Guardant Health among others.
Circulating Tumor Cells are expected to reach a market value of 2.01 billion USD by 2035.
The market value for Extracellular Vesicles is anticipated to be 0.38 billion USD in 2024.
Key growth drivers include advancements in technology and increased demand for non-invasive testing methods.
The market offers opportunities in personalized medicine and early cancer detection solutions.
Challenges include regulatory hurdles and the need for standardized methodologies across tests.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
